To investigate the association between adverse events recorded during critical care and mortality in out-of-hospital cardiac arrest patients treated with therapeutic hypothermia.
Prospective, observational, registry-based study.
Twenty-two hospitals in Europe and the United States.
Between October 2004 and October 2008, 765 patients were included.
Arrhythmias (7%–14%), pneumonia (48%), metabolic and electrolyte disorders (5%–37%), and seizures (24%) were common adverse events in the critical care period in cardiac arrest patients treated with therapeutic hypothermia, whereas sepsis (4%) and bleeding (6%) were less frequent. Sustained hyperglycemia (blood glucose >8 mmol/L for >4 hrs; odds ratio 2.3, 95% confidence interval 1.6–3.6, p < .001) and seizures treated with anticonvulsants (odds ratio 4.8, 95% confidence interval 2.9–8.1, p < .001) were associated with increased mortality in a multivariate model. An increased frequency of bleeding and sepsis occurred after invasive procedures (coronary angiography, intravascular devices for cooling, intra-aortic balloon pump), but bleeding and sepsis were not associated with increased mortality (odds ratio 1.0, 95% confidence interval 0.46–2.2, p = .91, and odds ratio 0.30, 95% confidence interval 0.12–0.79, p = .01, respectively).
Adverse events were common after out-of-hospital cardiac arrest. Sustained hyperglycemia and seizures treated with anticonvulsants were associated with increased mortality. Bleeding and infection were more common after invasive procedures, but these adverse events were not associated with increased mortality in our study.
From the Department of Clinical Sciences (NN, HF), Lund University, Lund, Sweden; Department of Anesthesiology and Intensive Care (NN), Helsingborg Hospital, Helsingborg, Sweden; Surgical Intensive Care Unit (KS), Oslo University Hospital, Ullevål, Norway; Department of Anesthesiology (JH), Oslo University Hospital, Rikshospitalet, Norway; Department of Critical Care (RRR), Maine Medical Center, Portland, ME, U.S.A.; Department of Anesthesiology and Intensive Care (SR), Uppsala University Hospital, Uppsala, Sweden; Department of Anesthesiology and Intensive Care (PS), Centre Hospitalier de Luxembourg, Luxembourg; Competence Centre for Clinical Research (FN), Lund University, Lund, Sweden; and Department of Emergency Medicine (HF), Lund University Hospital, Lund, Sweden.
Supported, in part, by the Scandinavian Critical Care Trials Group and the Scandinavian Society of Anesthesiology and Intensive Care, the Stig and Ragna Gorthon Foundation, the Torsten Birger Segerfalk Foundation, the Laerdal Foundation, the Gyllenstierna Krapperup Foundation (Nyhamnsläge, Sweden), and the Skåne County Council's research and development foundation.
The authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail: email@example.com